EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab

Paola Bracchi, Ernesto Zecca, Cinzia Brunelli iD, Rosalba Miceli, Gabriele Tinè, Massimo Maniezzo, Silvia Lo Dico, Mariangela Caputo, Morena Shkodra, Augusto T Caraceni

Cancer Medicine · 2023-09 · 12 (17) · 18317-18326

DOI: 10.1002/cam4.6429 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, online erschienen am 09.08.2023. Verfasst von Paola Bracchi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Assessing the incidence of Medication Related Osteonecrosis of the Jaw (MRONJ) in cancer patients with bone metastases receiving Denosumab (Dmab) and identifying potential risk factors.

Methods

A retrospective observational study on consecutive cancer patients with bone metastases, who received at least one dose of Dmab and one follow‐up visit. MRONJ crude cumulative incidence (CCI) was estimated considering death without MRONJ as competing event. Multiple regression models were used to study the association between MRONJ incidence and potential risk factors: age, cancer diagnosis, previous bisphosphonates, dental treatments before starting Dmab, extraction or other dental treatment during Dmab, chemotherapy, hormone therapy, and antiangiogenic (AA) agents concurrent use.

Results

On 780 patients included (median follow‐up 17 months), 54% and 18% had, respectively, breast and prostate cancer. The mean number of Dmab administration was 12. Fifty‐six patients developed MRONJ with a 24‐ and a 48‐month crude cumulative incidence of 5.7% (95% Cl: 4.2%–7.8%) and 9.8% (95% CI: 7.6%–12.7%), respectively. Higher MRONJ incidence was significantly associated with middle aged group (>56 and ≤73), both at univariate and multivariate analysis ( p = 0.029 and 0.0106). Dental treatments (Hazard Ratio [HR] = 3.67; p = 0.0001), dental extractions (HR = 23.40; p < 0.0001), and previous BP administration (HR = 2.62; p = 0.0024) were significantly associated with higher MRONJ incidence at multivariate Cox analysis. Although not statistically significant, MRONJ incidence was lower for patients receiving chemotherapy or hormone therapy and higher for those receiving AAs.

Conclusions

The results confirm a clinically relevant incidence of Dmab‐induced MRONJ. Dental treatments, especially extraction, during and before Dmab, constitute a serious risk factor. The role of AA concurrent administration deserves further investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsBisphosphonate-Associated Osteonecrosis of the JawBone NeoplasmsMaleMiddle AgedHumansDenosumabPrevalenceDiphosphonatesAngiogenesis InhibitorsRisk FactorsHormonesRetrospective Studies

Stichwörter der Autor:innen

Denosumabbone metastasiscancerosteonecrosis of the jawrisk factors

Substanzen

DenosumabBone Density Conservation AgentsDiphosphonatesAngiogenesis InhibitorsHormones

Autor:innen und Institutionen

  • Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Odontostomatology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy.

ORCID-Profile: Cinzia Brunelli

Zitieren

APA

Bracchi, P., Zecca, E., Brunelli, C., Miceli, R., Tinè, G., Maniezzo, M., Lo Dico, S., Caputo, M., Shkodra, M., & Caraceni, A. T. (2023). A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab. Cancer Medicine, 12(17), 18317-18326. https://doi.org/10.1002/cam4.6429

Vancouver

Bracchi P, Zecca E, Brunelli C, Miceli R, Tinè G, Maniezzo M, et al. A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab. Cancer Medicine. 2023;12(17):18317-18326. doi:10.1002/cam4.6429

BibTeX
@article{Bracchi2023,
  author = {Bracchi, Paola and Zecca, Ernesto and Brunelli, Cinzia and Miceli, Rosalba and Tinè, Gabriele and Maniezzo, Massimo and Lo Dico, Silvia and Caputo, Mariangela and Shkodra, Morena and Caraceni, Augusto T},
  title = {A real‐world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {17},
  pages = {18317--18326},
  doi = {10.1002/cam4.6429}
}
Kostenlos starten →